Belite Bio announced positive topline results from the phase 3 DRAGON trial of Tinlarebant in patients with Stargardt disease.Tinlarebant (LBS-008) is an oral therapy designed to reduce the accumulation of cytoxic bisretinoids, toxins that cause retina…
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Click here to read the Cover Story, “Cataract surgery lessens risk, development and burden of dementia.”There are currently more than 55 million people worldwide living with dementia, and this number is projected to double every 20 years.Dementia is a …
CHICAGO — Clinicians are increasingly concerned that AI will replace them, but experts said that this focus should shift towards how to leverage AI to solve problems within health care, according to speakers at a panel discussion.“There has been a know…
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced participation in an upcoming investo…
Many patients benefit from accessing their digital clinical notes, but significant disparities exist among groups that look at them.Black and Hispanic patients, those who do not use English as a preferred language, and single men all have a significant…